Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;157(2):280-288.
doi: 10.1053/j.gastro.2019.04.049. Epub 2019 May 13.

A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer

Andrea J Dwyer  1 , Caitlin C Murphy  2 , C Richard Boland  3 , Reese Garcia  4 , Heather Hampel  5 , Paul Limburg  6 , Jan Lowery  7 , Ann G Zauber  8 , Stephen Waring  9 , Sharyn Worrall  4 , Jose Perea  10 , Rebecca Siegel  11 , Jeffrey Lee  12 , Christine Molmenti  13 , Cynthia L Sears  14 , Phillip Buckhaults  15 , Richard Hayes  16 , Hisham Hussan  17 , Noel de Miranda  18 , Claire Palles  19 , Luis Diaz  8 , Mingyang Song  20 , Andrea Cercek  8 , Christopher H Lieu  7 , Swati G Patel  21 , Jordan J Karlitz  22 , Yin Cao  23 , Josh Demb  3 , Patrick Blatchford  7 , Betsy Risendal  24 , Elsa S Staples  24 , Anil Wali  25 , Phil Daschner  26 , Holli Loomans-Kropp  26 , R Flores  26 , Caleb L Levell  27 , Karen Wehling  28 , Jessica Martin  28 , Curt Pesmen  28 , Violet Kuchar  29 , Ryan Soisson  30 , Anjee Davis  4 , Dennis Ahnen  7
Affiliations

A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer

Andrea J Dwyer et al. Gastroenterology. 2019 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

C. Richard Boland, MD, Presented several lectures for Ambry Genetics

Heather Hampel, CGN, Ms. Hampel is on the scientific advisory board for InVitae Genetics and Genome Medical and has stock in Genome Medical. She has performed collaborative research with Ambry Genetics, InVitae Genetics, and Myriad Genetic Laboratories, Inc.

Paul Limburg, MD, Dr. Limburg serves as co-Chief Medical Officer for Exact Sciences through a contracted services agreement with Mayo Clinic. Dr. Limburg and Mayo Clinic have contractual rights to receive royalties through this agreement.

Cynthia L. Sears, MD, Bristol Meyers Squibb (ongoing research support) Merck Lecture on Microbiome and CRC

Phillip Buckhaults PhD, Reports receiving a commercial research grant from Janssen Research and Development

Luis Diaz, MD, L. Diaz (LAD) is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics. LAD holds equity in PapGene, PGDx and Neophore. He is a paid consultant for PGDx and Neophore. He is an uncompensated consultant for Merck but has received research support for trials from Merck. LAD is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy (WO2016077553A1) from Johns Hopkins University. Some of these licenses and relationships are associated with equity or royalty payments to LAD. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. In addition, in the past 5 years, LAD has participated as a paid consultant for Merck and for one-time engagements with Caris, Lyndra, Genocea Biosciences, Illumina and Cell Design Labs.

Jordan J. Karlitz, MD, Advisor, Exact Sciences Consultant and Speaker’s Bureau Myriad Genetics

Dennis Ahnen, MD, Speakers bureau for Ambrose genetics.Scientific advisor for Cancer Prevention Pharmaceuticals

Figures

Figure 1:
Figure 1:
Incidence rates rose by 50% (from 1995 through 2015) in ages 20–49 years and declined by 50% (1985 through 2015) in ages 50+
Figure 2:
Figure 2:
Incidence rate ratios by birth cohort (1930–1990)
Figure 3:
Figure 3:
Structure and flow of activities at the Fight CRC EAO February 2019 working meeting
Figure 4:
Figure 4:
Major themes, risk factors of EAO CRC incidence or adenoma development, timing of exposures and stratification of risk factor examination.
Figure 5:
Figure 5:
Early Age Onset Working Meeting Attendees: Denver, Colorado, February 1, 2019
See this image and copyright information in PMC

Comment in

References

    1. Surveillance Epidemiology, and Results End (SEER) Program SEER*Stat Database: Incidence - SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, Nov 2017 Sub (1975–2015) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018.
    1. Singh KE, Taylor TH, Pan CG, Stamos MJ, & Zell JA (2014). Colorectal Cancer Incidence Among Young Adults in California. Journal of Adolescent and Young Adult Oncology,3(4). doi:10.1089/jayao.2014.0006 - DOI - PMC - PubMed
    1. Pearlman R, Frankel WL (et al). Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncology Published online December 15, 2016 - PMC - PubMed
    1. Murphy CC, Singal AG, Baron JA, et al. Decrease in incidence of young-onset colorectal cancer before recent increase. Gastroenterology 2018. - PMC - PubMed
    1. Surveillance Epidemiology, and Results End (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2017 Sub (1973–2015), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.